Marketed by Idorsia in North America and Europe and is available in key Asia-Pacific and Middle East markets through commercial partnerships. Strategic commercial partnerships in Latin America and the Middle East continue to expand QUVIVIQ's geographic reach and commercial scale.
TRYVIO™ / JERAYGO™ (aprocitentan)*
Dual endothelin receptor antagonist
Difficult-to-control / Resistant hypertension in combination with other antihypertensives
Commercially available in the US. Approved in the EU, UK, Switzerland, and Canada.
Clinical pipeline
Compound
Mechanism of action
Target indication
Status
Selatogrel*
P2Y₁₂ inhibitor
Acute myocardial infarction
Worldwide development and commercialization rights with Viatris. Phase 3 “SOS-AMI” recruiting – targeting completion of enrollment in 2026
Cenerimod*
S1P₁ receptor modulator
Systemic lupus erythematosus
Worldwide development and commercialization rights with Viatris. Phase 3 “OPUS” program completed enrollment – targeting data read out in H1 2027
Lucerastat
Glucosylceramide synthase inhibitor
Fabry disease
FAB-KLEAR, the pivotal Phase 3 kidney biopsy study, is currently recruiting. Together with FAB-SWITCH, the Phase 3 program is expected to support a regulatory filing as early as 2029
Daridorexant
Dual orexin receptor antagonist
Pediatric insomnia
Positive Phase 2 in pediatric insomnia presented at Sleep Europe 2026 – company in discussions with health authorities on a Phase 3 program
Canverixan
ACKR3 (CXCR7) receptor antagonist
Progressive multiple sclerosis
Proof-of-concept study currently recruiting – readout expected in Q2 2028
ACT-777991
CXCR3 antagonist
Vitiligo
Proof-of-concept study currently recruiting – readout expected by year -end 2027
IDOR-1134-2831
Synthetic glycan vaccine
Clostridium difficile infection
Phase 1 data showing safety and dose-dependent immunogenicity – partnership discussions activated
*Idorsia has transferred its rights for aprocitentan, cenerimod and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the financial report from Idorsia Investments SARL.